Stocktoria
BIOCRYST PHARMACEUTICALS INC BCRX
BIOCRYST PHARMACEUTICALS INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $874.8M | $450.7M | $331.4M | $270.8M | $157.2M | $17.8M | $48.8M | $20.7M | $25.2M | $26.4M |
| R&D expense | $166.1M | $174.6M | $216.6M | $253.3M | $208.8M | $123.0M | $107.1M | $84.9M | $67.0M | $61.0M |
| SG&A expense | $348.6M | $266.3M | $214.1M | $159.4M | $118.8M | $67.9M | $37.1M | $29.5M | $13.9M | $11.3M |
| Operating income | $341.0M | -$2.5M | -$103.7M | -$148.4M | -$177.7M | -$174.8M | -$99.5M | -$94.2M | -$57.4M | -$48.6M |
| Interest expense | — | — | $108.2M | $99.1M | $59.3M | $14.5M | $11.9M | $9.2M | $8.6M | $6.5M |
| Income tax | $3.5M | $1.9M | $310,000 | $2.7M | $2.3M | $0 | $0 | $0 | $0 | $0 |
| Net income | $263.9M | -$88.9M | -$226.5M | -$247.1M | -$184.1M | -$182.8M | -$108.9M | -$101.3M | -$65.8M | -$55.1M |
| EPS (diluted) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | — | — | — | — |
| Operating cash flow | $347.4M | -$52.0M | -$95.1M | -$161.8M | -$142.2M | -$135.1M | -$89.6M | -$92.6M | -$41.1M | -$53.4M |
| Free cash flow | — | — | — | — | — | — | -$89.9M | -$92.9M | -$41.5M | — |
| Cash & equivalents | $89.7M | $104.7M | $110.6M | $304.8M | $504.4M | $272.1M | $114.2M | $26.7M | $50.3M | $22.1M |
| Inventory | $5.4M | $8.1M | $28.7M | $27.5M | $15.8M | $7.0M | $0 | $1.6M | — | $500,000 |
| Total assets | $514.2M | $490.4M | $517.0M | $550.0M | $588.2M | $334.7M | $175.3M | $146.8M | $178.3M | $89.8M |
| Total liabilities | $633.3M | $966.4M | $972.5M | — | — | — | — | — | — | — |
| Shareholders' equity | -$119.2M | -$475.9M | -$455.5M | -$294.6M | -$107.0M | -$19.3M | $38.3M | $49.2M | $83.8M | $1.6M |
Growth · year-over-year · Revenue CAGR 47.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +94.1% | +36.0% | +22.4% | +72.3% | +782.4% | -63.5% | +136.5% | -18.0% | -4.4% | -45.4% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.